A Korean cohort study indicated that patients with lung cancer undergoing ICI therapy had a lower risk of VZV infection, possibly due to the enhanced function of VZV-specific CD4+ and CD8+ T cells [2]. This evidence concerns the gene CD8A and lung cancer.